Viive M Howell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3523632/publications.pdf

Version: 2024-02-01

57 1,449 20 36 g-index

papers citations h-index 20 3.45221

58 58 58 2478 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias. American Journal of Surgical Pathology, 2006, 30, 1140-1149.	3.7	213
2	Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 434-441.	3.6	120
3	The Extracellular Matrix in Epithelial Ovarian Cancer – A Piece of a Puzzle. Frontiers in Oncology, 2015, 5, 245.	2.8	101
4	Gene Expression of Parathyroid Tumors. Cancer Research, 2004, 64, 7405-7411.	0.9	96
5	Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration. International Journal of Molecular Sciences, 2018, 19, 205.	4.1	72
6	Acinar cell density at the pancreatic resection margin is associated with post-pancreatectomy pancreatitis and the development of postoperative pancreatic fistula. Hpb, 2018, 20, 432-440.	0.3	45
7	Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 2018, 8, 314.	2.8	43
8	Evidence for a direct role of the disease modifier SCNM1 in splicing. Human Molecular Genetics, 2007, 16, 2506-2516.	2.9	41
9	CDC73/HRPT2 CpG island hypermethylation and mutation of 5′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer, 2010, 17, 273-282.	3.1	37
10	Low-Dose Spironolactone Prevents Apoptosis Repressor With Caspase Recruitment Domain Degradation During Myocardial Infarction. Hypertension, 2012, 59, 1164-1169.	2.7	37
11	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 2015, 6, 44551-44562.	1.8	37
12	Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Scientific Reports, 2017, 7, 10374.	3.3	33
13	Rapid Mutation Scanning of Genes Associated with Familial Cancer Syndromes Using Denaturing High-Performance Liquid Chromatography. Neoplasia, 2001, 3, 236-244.	5.3	31
14	Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology, 2013, 6, 742-IN34.	3.7	31
15	Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma. Frontiers in Oncology, 2021, 11, 633210.	2.8	30
16	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 2020, 142, 34-40.	2.0	27
17	Expression of long noncoding RNAs in cancerâ€nssociated fibroblasts linked to patient survival in ovarian cancer. Cancer Science, 2020, 111, 1805-1817.	3.9	25
18	Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosomes and Cancer, 2015, 54, 1-19.	2.8	23

#	Article	IF	CITATIONS
19	Streptavidin: A Novel Immunostimulant for the Selection and Delivery of Autologous and Syngeneic Tumor Vaccines. Cancer Immunology Research, 2014, 2, 469-479.	3.4	22
20	Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. European Journal of Surgical Oncology, 2019, 45, 218-224.	1.0	22
21	Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy. Frontiers in Oncology, 2020, 10, 237.	2.8	22
22	Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opinion on Medical Diagnostics, 2007, 1, 377-392.	1.6	21
23	Are In Vitro Human Blood–Brain–Tumor-Barriers Suitable Replacements for In Vivo Models of Brain Permeability for Novel Therapeutics?. Cancers, 2021, 13, 955.	3.7	21
24	Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 2014, 4, 6152.	3.3	20
25	Sleeping Beauty – A mouse model for all cancers?. Cancer Letters, 2012, 317, 1-8.	7.2	19
26	Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6091-6096.	7.1	19
27	From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell and Developmental Biology, 2014, 27, 118-127.	5.0	19
28	Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?. Seminars in Cell and Developmental Biology, 2014, 27, 106-117.	5.0	19
29	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. The Cochrane Library, 2020, 2020, CD013238.	2.8	19
30	The Tayâ€Sachs disease prevention program in Australia: Sydney pilot study. Medical Journal of Australia, 1995, 163, 298-300.	1.7	19
31	A molecular diagnosis of hyperparathyroidism—Jaw tumor syndrome in an adolescent with recurrent kidney stones. Journal of Pediatrics, 2004, 145, 567.	1.8	16
32	Rapid Mutation Screening for HRPT2 and MEN1 Mutations Associated with Familial and Sporadic Primary Hyperparathyroidism. Journal of Molecular Diagnostics, 2006, 8, 559-566.	2.8	16
33	Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. PLoS ONE, 2020, 15, e0226444.	2.5	16
34	Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches. International Journal of Molecular Sciences, 2020, 21, 4806.	4.1	14
35	The role of proteomics in the age of immunotherapies. Mammalian Genome, 2018, 29, 757-769.	2.2	12
36	BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLoS ONE, 2018, 13, e0203003.	2.5	10

#	Article	IF	Citations
37	A Targeted Deleterious Allele of the Splicing Factor SCNM1 in the Mouse. Genetics, 2008, 180, 1419-1427.	2.9	8
38	ROS1-Rearranged Non–Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses. Clinical Lung Cancer, 2018, 19, 457-459.	2.6	8
39	<i>ALK</i> -Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. Oncologist, 2020, 25, 641-649.	3.7	8
40	Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. Proteomics - Clinical Applications, 2015, 9, 1078-1086.	1.6	7
41	Pattern of care and survival of anaplastic lymphoma kinase rearranged non–small cell lung cancer (<i>ALK</i> + NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e275-e282.	1.1	6
42	Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. European Journal of Surgical Oncology, 2020, 46, 1539-1542.	1.0	6
43	Differential effects of radiation fractionation regimens on glioblastoma. Radiation Oncology, 2022, 17, 17.	2.7	6
44	Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Journal of Clinical Medicine, 2021, 10, 2700.	2.4	5
45	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4651.	3.7	5
46	Genetically Engineered Insertional Mutagenesis in Mice to Model Cancer: Sleeping Beauty. Methods in Molecular Biology, 2014, 1194, 367-383.	0.9	4
47	Overlooked potential of positrons in cancer therapy. Scientific Reports, 2021, 11, 2475.	3.3	4
48	P2.01-012 Acquired Chemotherapy Resistance in vitro: miRNA Profiles of Chemotherapy Resistant Squamous Lung Cancer Cell Lines. Journal of Thoracic Oncology, 2017, 12, S790-S791.	1.1	3
49	Why the dual origins of high grade serous ovarian cancer matter. Nature Communications, 2020, 11, 1200.	12.8	3
50	Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model. Journal of Visualized Experiments, 2015, , .	0.3	2
51	29th International Mammalian Genome Conference meeting report. Mammalian Genome, 2016, 27, 169-178.	2.2	2
52	CBIO-10. GLIOBLASTOMA RECURRENCE CORRELATES WITH INCREASED APE1 AND AN IMMUNE-SUPPRESSION MICROENVIRONMENT. Neuro-Oncology, 2017, 19, vi34-vi35.	1.2	2
53	Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors. Hormones and Cancer, 2015, 6, 142-152.	4.9	1
54	Matching treatment strategies to clinical phenotype: Biomarker-driven selection for neoadjuvant therapy in pancreatic cancer Hpb, 2019, 21, S200.	0.3	1

#	Article	IF	CITATIONS
55	Mice and men working together for over 100 years in the fight against cancer. Seminars in Cell and Developmental Biology, 2014, 27, 52-53.	5.0	O
56	TMIC-39. UNRAVELLING THE TUMOUR MICROENVIRONMENT OF GLIOMA. Neuro-Oncology, 2018, 20, vi264-vi265.	1,2	0
57	Introduction to Mammalian Genome special issue: inflammation and immunity in cancer. Mammalian Genome, 2018, 29, 691-693.	2.2	O